TPD52L1-ROS1 Rearrangement as a New Acquired Resistance Mechanism to Osimertinib That Responds to Crizotinib in Combination With Osimertinib in Lung Adenocarcinoma

Detalles Bibliográficos
Autores principales: Xu, Caihua, Li, Dapeng, Duan, Weiming, Tao, Min
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474410/
https://www.ncbi.nlm.nih.gov/pubmed/34589932
http://dx.doi.org/10.1016/j.jtocrr.2020.100034

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474410/
https://www.ncbi.nlm.nih.gov/pubmed/34589932
http://dx.doi.org/10.1016/j.jtocrr.2020.100034

Ejemplares similares